{"id":"kp-100it","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL4297297","moleculeType":"Small molecule","molecularWeight":"372.42"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"KP-100IT works by selectively modulating the sphingosine-1-phosphate 1 (S1P1) receptor, which plays a crucial role in the regulation of immune cell trafficking and function. This mechanism of action has been shown to have therapeutic potential in various inflammatory and autoimmune diseases.","oneSentence":"KP-100IT is a small molecule that targets the S1P1 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:17:58.254Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing forms of multiple sclerosis"}]},"trialDetails":[{"nctId":"NCT04475224","phase":"PHASE3","title":"Phase 3 Study of KP-100IT in Subjects With Acute Spinal Cord Injury","status":"UNKNOWN","sponsor":"Kringle Pharma, Inc.","startDate":"2020-07-13","conditions":"Acute Spinal Cord Injury","enrollment":25},{"nctId":"NCT02193334","phase":"PHASE1, PHASE2","title":"Phase I/II Study of KP-100IT in Acute Spinal Cord Injury","status":"COMPLETED","sponsor":"Kringle Pharma, Inc.","startDate":"2014-06-30","conditions":"Spinal Cord Injuries","enrollment":45}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Hepatocyte Growth Factor","HGF"],"phase":"phase_3","status":"active","brandName":"KP-100IT","genericName":"KP-100IT","companyName":"Kringle Pharma, Inc.","companyId":"kringle-pharma-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"KP-100IT is a small molecule that targets the S1P1 receptor. Used for Relapsing forms of multiple sclerosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}